Recruiting
Phase 1
Phase 2

MK-3120

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT07222488

Conditions

Bladder Cancer

Urinary Bladder Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MK-3120

Study Details

Brief summary:

Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctors first remove the tumor with a procedure called transurethral resection of the bladder tumor (TURBT). Researchers want to learn if using MK-3120, the study medicine, can treat HR NMIBC after TURBT. The goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Conditions

Bladder Cancer

Urinary Bladder Neoplasms

Study ID

NCT07222488

Start date

Dec 9, 2025

Status verified date

Sep, 2026

Completion date

Feb 28, 2029

Anticipated

Primary completion date

Feb 28, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Has histologically confirmed carcinoma in situ (CIS) +/- papillary high-risk non-muscle invasive bladder cancer (NMIBC), confirmed locally.
  • Is an individual whose most recent transurethral resection of bladder tumor (TURBT) was performed within 12 weeks before allocation and showed high-risk NMIBC histology. For individuals with papillary tumors (Ta and T1), a complete TURBT must have been performed, as characterized by attainment of a visually complete resection of all papillary tumors (Ta and T1).
  • Is either: a) Bacillus Calmette-Guérin (BCG)-naïve, defined as either having never received BCG or having received BCG more than 2 years before CIS +/- papillary high-risk NMIBC recurrence. Recurrence must be at least 24 months from the last exposure to BCG with evidence of complete response during the 2-year period post-BCG OR; b) BCG-exposed and received adequate BCG therapy and had recurrence of CIS +/- papillary high-risk NMIBC >12 months but ≤24 months after the last BCG dose.
  • Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy.
  • Participants who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation.
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.

Exclusion Criteria:

  • Has history of or current locally advanced (ie, T2, T3, T4) or metastatic urothelial cancer (UC).
  • Has concurrent extravesical (ie, urethra, ureter, renal pelvis) non-muscle invasive UC or history of extravesical non-muscle invasive UC that recurred within the last 2 years.
  • Has active total bladder incontinence, active urinary tract infection, neurogenic bladder, or urethral stricture.
  • Has a condition that would prohibit normal voiding (or holding bladder voiding for 1 to 2 hours).
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to >470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention.
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years.
  • Has known active central nervous system metastases and/or carcinomatous meningitis.
  • Has active infection requiring systemic therapy.
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, or has current pneumonitis/ILD.
  • Has not adequately recovered from major surgery or has ongoing surgical complications.

Study Design

Enrollment

45 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: MK-3120

Participants will be administered MK-3120 once weekly for the first 6 weeks, followed by once monthly for 9 months.

Interventions

MK-3120

Intravesical administration at one of three doses per protocol

Primary outcome measure

  • Number of Participants Who Experience a Dose-limiting Toxicity (DLT) [ Time Frame: Up to approximately 5 weeks ]
  • Number of Participants Who Experience One or More Adverse Events (AEs) [ Time Frame: Up to approximately 24 months ]
  • Number of Participants Who Discontinue Study Treatment Due to AEs [ Time Frame: Up to approximately 12 months ]

Central Contacts and Locations

Central contacts

Toll Free Number

1-888-577-8839Trialsites@msd.com

Locations

Michael G Oefelein Clinical Trials ( Site 0005)

Recruiting

Bakersfield, California, United States, 93301

Contacts

Study Coordinator

661-310-1063

Rutgers Cancer Institute of New Jersey ( Site 0007)

Recruiting

New Brunswick, New Jersey, United States, 08901

Contacts

Study Coordinator

732-235-7530

Carolina Urologic Research Center ( Site 0006)

Recruiting

Myrtle Beach, South Carolina, United States, 29572

Contacts

Study Coordinator

843-449-1010

Urology Austin, PLLC ( Site 0008)

Recruiting

Austin, Texas, United States, 78759

Contacts

Study Coordinator

512-410-3773

CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011)

Recruiting

Québec, Quebec, Canada, G1J 1Z4

Contacts

Study Coordinator

418-525-4444

More Information

Sponsor

Merck Sharp & Dohme LLC

Last update posted

Sep 3, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-09-03.